Pharma Industry News

An Alzheimer’s drugmaker is accused of data ‘manipulation.’ Should its trials be stopped?

Cassava Sciences’ beleaguered investigational Alzheimer’s therapy is in two phase 3 studies.

Cassava Sciences’ beleaguered investigational Alzheimer’s therapy is in two phase 3 studies.

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]